Ключевые слова:
cardiovascular diseases, ischemic heart disease, diabetes mellitus, dyslipidemiaБиблиографические ссылки
Aimo A., Castiglione V., Borrelli C. et al. Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies // Eur J Prev Cardiol. – 2020. – Vol. 27. – P. 494–510.
Borlaug BA The pathophysiology of heart failure with preserved ejection fraction // Nat Rev Cardiol. – 2014. – Vol. 11(9). – P. 507–515.
Brandt MM, Nguyen ITN, Krebber MM et al. Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of heart failure with preserved ejection fraction // J Cell Mol Med. – 2019. – Vol. 23(10). – P. 6666–6678.
Buliga-Finis ON, Ouatu A., Badescu MC, Dima N. et al. Beyond the Cardiorenal Syndrome: Pathophysiological Approaches and Biomarkers for Renal and Cardiac Crosstalk. Diagnostics. 2022;12:773.
Chen YT, Wong LL, Liew OW, Richards AM Heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF): the diagnostic value of circulating microRNAs // Cells. – 2019. – Vol. 8. – doi: 10.3390/cells8121651.
Clinical outcomes after ablation and pacing therapy for atrial fibrillation / MA Wood [et al.] // Circulation. – 2000. – Vol. 101 (10). – P. 1138–1144. – doi: 10.1161/01.cir.101.10.1138.
Di LL, Reeves PB, Bellasi A, Ronco C. Cardiorenal Syndrome in Acute Kidney Injury. Semin Nephrol. 2019;39(1):31–40.
Farmakis D., Parissis J., Filippatos G. Acute heart failure: treatment. The ESC Textbook of Cardiovascular Medicine. Oxford: Oxford University Press; 2018. doi: 10.1093/med/9780198784906.003.0441
Franssen C., Chen S., Hamdani N., Paulus WJ From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress // Heart. – 2016. – Vol. 102. – P. 320–330.
Freed BH, Daruwalla V, Cheng JY et al. Prognostic Utility and Clinical Significance of Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction: Importance of Left Atrial Strain // Circ Cardiovasc Imag. – 2016. – Vol. 9. – doi: 10.1161/CIRCIMAGING.115.003754.
Friebel J., Weithauser A., Witkowski M. et al. Protease-activated receptor 2 deficiency mediates cardiac fibrosis and diastolic dysfunction // Eur Heart J. – 2019. – Vol. 40(40). – P. 3318–3332.
Gan GCH, Ferkh A., Boyd A., Thomas L. Left atrial function: evaluation by strain analysis // Cardiovasc Diagn Ther. – 2018. – Vol. 8(1). – P. 29–46.
Gaytan SL, Beaven E., Gadad SS, Nurunnabi M. Progress and prospect of nanotechnology for cardiac fibrosis treatment // Interdiscip Med. – 2023. – Vol. 1(4). – doi: 10.1002/INMD.20230018.
Ge J. Coding proposal on phenotyping heart failure with preserved ejection fraction: a practical tool for facilitating etiology-oriented therapy // Cardiol J. – 2020. – Vol. 27(1). – P. 97–8.
Gevaert AB, Boen JR, Segers VF, Van Craenenbroeck EM Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology // Front Physiol. – 2019. – Vol. 10. – doi: 10.3389/fphys.2019.00638.
Gevaert AB, Shakeri H, Leloup AJ et al. Endothelial senescence contributes to heart failure with preserved ejection fraction in an aging mouse model // Circ Heart Fail. – 2017. – Vol. 10(6). – doi: 10.1161/CIRCHEARTFAILURE.116.003806.
Hahn VS, Knutsdottir H., Luo X. et al. Myocardial gene expression signatures in human heart failure with preserved ejection fraction // Circulation. – 2021. – Vol. 143. – P. 120–134.
Henning RJ Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction // World J Cardiol. – 2020. – Vol. 12(1). – P. 7–25.
Indorkar R., Kwong R.Y., Romano S. et al. Global Coronary Flow Reserve Measured During Stress Cardiac Magnetic Resonance Imaging Is an Independent Predictor of Adverse Cardiovascular Events // JACC Cardiovasc Imaging. – 2018. – Vol. 12(8 Pt 2). – P. 1686–1695.
Kanagala P., Arnold JR, Singh A. et al. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach // PLoS One. – 2020. – Vol. 15(4). – doi: 10.1371/journal.pone.0232280.
Kumar AA, Kelly DP, Chirinos JA Mitochondrial dysfunction in heart failure with preserved ejection fraction // Circulation. – 2019. – Vol. 139. – P. 1435–1450.
Lewis G. A., Rosala-Hallas A., Dodd S. et al. Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction // J Cardiovasc Transl Res. – 2022. – Vol. 15(6). – P. 1436–1443.
Lindman BR, Davila-Roman VG, Mann DL et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study // J Am Coll Cardiol. – 2014. – Vol. 64. – P. 541–549.
Masip J., Frank Peacok W., Arrigo M. et al. Acute Heart Failure Study Group of the Association for Acute Cardiovascular Care (ACVC) of the European Society of Cardiology. Acute Heart Failure in the 2021. ESC Heart Failure Guidelines. Eur Heart J Acute Cardiovasc Care. 2022;11(2):173–185. doi: 10.1093/ ehjacc /zuab122
Melenovsky V., Hwang SJ., Redfield MM et al. Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction // Circ Heart Fail. – 2015. – Vol. 8. – P. 295–303.
Michels da Silva D., Langer H., Graf T. Inflammatory and molecular pathways in heart failure-ischemia, HFpEF and transthyretin cardiac amyloidosis // Int J Mol Sci. – 2019. – Vol. 20(9). – doi: 10.3390/ijms20092322.
Obokata M., Reddy YNV, Borlaug BA Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods // JACC Cardiovasc Imaging. – 2020. – Vol. 13(1 Pt 2). – P. 245–257.
Packer M. Derangements in adrenergic-adipokine signaling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction // Eur J Heart Fail. – 2018. – Vol. 20. – P. 873–878.
Paulus WJ, Dal Canto E. Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction // JACC Heart Fail. – 2018. – Vol. 6(1). – P. 1–7.
Pieske B., Tschope C., de Boer RA et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) // Eur J Heart Fail. – 2020. – Vol. 22(3). – P. 391–412.
Ponikowski P, Voors AA, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure Association (HFA) of the ESC // Eur J Heart Fail. – 2016. – Vol. 18(8). – P. 891–975.
Rey JR, Caro -Codón J., Rosillo SO, Iniesta Á. M. et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020; 22:2205 –2215.
Rodriguez P., Sassi Y., Troncone L. et al. Deletion of delta-like 1 homologue accelerates fibroblast-myofibroblast differentiation and induces myocardial fibrosis // Eur Heart J. – 2019. – Vol. 40(12). – P. 967–978.
Sarma S., Stoller D., Hendrix J. et al. Mechanisms of Chronotropic Incompetence in heart failure with preserved ejection fraction // Circ Heart Fail. – 2020. – Vol. 13(3). – doi: 10.1161/CIRCHEARTFAILURE.119.006331.
Shah SJ, Borlaug BA, Kitzman DW et al. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary // Circulation. – 2020. – Vol. 141(12). – P. 1001–1026.
Singleton MJ, Nelson MB, Samuel TJ et al. Left Atrial Stiffness Index Independently Predicts Exercise Intolerance and Quality of Life in Older, Obese Patients With Heart Failure With Preserved Ejection Fraction // J Card Fail. – 2022. – Vol. 28(4). – P. 567–575.
Sorop O., Heinonen I., van Kranenburg M. et al. Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening // Cardiovasc Res. – 2018. – Vol. 114(7). – P. 954–964.
Sweeney M., Corden B., Cook SA Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? // EMBO Mol Med. – 2020. – Vol. 12(10). – doi: 10.15252/emmm.201910865.
Van Deursen V.M., Urso R., Laroche C., Damman K. et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16(1):103–111.
Yamamoto E., Hirata Y., Tokitsu T. et al. The pivotal role of eNOS uncoupling in vascular endothelial dysfunction in patients with heart failure with preserved ejection fraction // Int J Cardiol. – 2015. – Vol. 190. – P. 335–337.
Zhazykbayeva S., Pabel S., Mugge A., Sossalla S., Hamdani N. The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases // Biophys Rev. – 2020. – Vol. 12(4). – P. 947–968.
Zhou Y., Zhu Y., Zeng J. Research Update on the Pathophysiological Mechanisms of Heart Failure with Preserved Ejection Fraction // Curr Mol Med. – 2023. – Vol. 23(1). – P. 54–62.
Zile MR, Baicu CF, Ikonomidis JS et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin // Circulation. – 2015. – Vol. 131(14). – P. 1247–1259.